within Pharmacolibrary.Drugs.ATC.G;

model G03AC05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.32,
    Cl             = 0.025,
    adminDuration  = 600,
    adminMass      = 0.16,
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0013833333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Megestrol is a synthetic progestin, primarily used as megestrol acetate to stimulate appetite and promote weight gain in patients with anorexia, cachexia, or significant weight loss due to cancer or AIDS. It has also been used in the palliative treatment of advanced breast and endometrial cancers. Megestrol acetate is approved and used in clinical practice today for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics parameters estimated for healthy adult subjects after oral administration, as published data are scarce. Estimates are derived from pharmacokinetic summaries and reviews where explicit PK parameters are not fully detailed.</p><h4>References</h4><ol><li><p> (2007). Megestrol acetate NCD oral suspension -- Par Pharmaceutical: megestrol acetate nanocrystal dispersion oral suspension, PAR 100.2, PAR-100.2. <i>Drugs in R&amp;D</i> 8(4) 251–254. DOI:<a href=&quot;https://doi.org/10.2165/00126839-200708040-00005&quot;>10.2165/00126839-200708040-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17596111/&quot;>https://pubmed.ncbi.nlm.nih.gov/17596111</a></p></li><li><p>Scott, LJ, &amp; Wiseman, LR (1999). Exemestane. <i>Drugs</i> 58(4) 675–682. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199958040-00007&quot;>10.2165/00003495-199958040-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10551437/&quot;>https://pubmed.ncbi.nlm.nih.gov/10551437</a></p></li><li><p>Li, Y, et al., &amp; Yang, SG (2015). Nanomemulsion of megestrol acetate for improved oral bioavailability and reduced food effect. <i>Archives of pharmacal research</i> 38(10) 1850–1856. DOI:<a href=&quot;https://doi.org/10.1007/s12272-015-0604-9&quot;>10.1007/s12272-015-0604-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25893430/&quot;>https://pubmed.ncbi.nlm.nih.gov/25893430</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G03AC05;
